PremiumSVRA

In-depth analysis ahead of drug approval for a rare disease

The company is developing a drug for a rare lung disease with a potential market of $1.1 billion, and is expected to receive approval in November.

By the SpyStocks desk · 3mo ago · 2 min read

The rest of this story is for members

The rest is for members

The story continues: the full timeline, the transaction ranges, and the names the forms carry.

Premium comes through the Telegram channel. Already have a code? Sign in to activate it.

Telegram@TheAmericanDream5

Real-time buys, sweeps, and trading halts from the desk. Free to join.